XML 74 R59.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Collaboration and License Agreements (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2020 | Mar. 31, 2020 | Nov. 30, 2015 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019
Collaboration and License Agreements [Abstract] |  |  |  |  |  |
Sanofi Upfront Payment |  |  | $ 300,000 |  |  |
Sanofi Revenue Allocated to Development Deliverable |  |  | 113,800 |  |  |
Sanofi Revenue Allocated to License Deliverable |  |  | 126,800 |  |  |
Sanofi Revenue Recognized |  |  |  |  |  | $ 286,000
Sanofi Revenue Allocated to Funding Deliverable |  |  | $ 59,400 |  |  |
Ipsen Total Payments To Date |  |  |  | $ 47,200 |  |
Ipsen Revenue Recognized |  |  |  |  | $ 300 | 4,900
Ipsen product sales |  |  |  |  |  | 1,300
Settlement Payment from Termination |  |  |  |  |  | 208,000
Sanofi Termination Agreement |  |  |  |  |  | 260,000
Sanofi Deferred Revenue from Termination |  |  |  |  |  | 23,500
Subsequent Event [Line Items] |  |  |  |  |  |
Settlement Payment from Termination |  |  |  |  |  | $ 208,000
Subsequent Event |  |  |  |  |  |
Collaboration and License Agreements [Abstract] |  |  |  |  |  |
Settlement Payment from Termination | $ 2,700 | $ 12,100 |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |
Settlement Payment from Termination | $ 2,700 | $ 12,100 |  |  |  |
Legal Fees |  |  |  | $ 2,100 |  |

X
- Definition Collaboration and License Agreements [Abstract] + References No definition available. + Details
Name: | lxrx_CollaborationAndLicenseAgreementsAbstract
Namespace Prefix: | lxrx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period. + References No definition available. + Details
Name: | lxrx_IpsenRevenueRecognized
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the total all payments under the agreement to date. + References No definition available. + Details
Name: | lxrx_IpsenTotalPaymentsToDate
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of product sales to Ipsen. + References No definition available. + Details
Name: | lxrx_Ipsenproductsales
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sanofi Deferred Revenue from Termination + References No definition available. + Details
Name: | lxrx_SanofiDeferredRevenueFromTermination
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the development services deliverable. + References No definition available. + Details
Name: | lxrx_SanofiRevenueAllocatedtoDevelopmentDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the funding deliverable. + References No definition available. + Details
Name: | lxrx_SanofiRevenueAllocatedtoFundingDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the amount of the upfront payment allocated to the license deliverable. + References No definition available. + Details
Name: | lxrx_SanofiRevenueAllocatedtoLicenseDeliverable
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period. + References No definition available. + Details
Name: | lxrx_SanofiRevenueRecognized
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sanofi Termination Agreement + References No definition available. + Details
Name: | lxrx_SanofiTerminationAgreement
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate satagliflozin. This represents the upfront payment under the agreement. + References No definition available. + Details
Name: | lxrx_SanofiUpfrontPayment
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Settlement Payment from Termination + References No definition available. + Details
Name: | lxrx_SettlementPaymentFromTermination
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_LegalFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References No definition available. + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |